Drug Trial Radar · NCT03712124
A Study of CNSA-001 in Women With Diabetic Gastroparesis
Last checked: Nov 20, 2026Latest source record: Jan 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Feb 27, 2019
Primary completion
Sep 8, 2019
Study completion Oct 8, 2019
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or placebo. All participants will receive the standard of care for diabetic gastroparesis.
Conditions
- Gastroparesis
Interventions
CNSA-001Drug
CNSA-001 Powder for Suspension
PlaceboDrug
Placebo Suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14Time frame: Baseline (Day 1), Day 14
- Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 28Time frame: Baseline (Day 1), Day 28
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
GW Research, Inc.
Chula Vista, California
LMG Research
Miami, Florida
Indiana University Hospital
Indianapolis, Indiana
University of Louisville
Louisville, Kentucky
Johns Hopkins University
Baltimore, Maryland
Clinical Research Solutions, LLC
Jackson, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.